Zhitong Finance App News, Luye Pharmaceutical (02186.HK) announced that LY03015, a new molecular entity independently developed by the Group, has successfully completed bridging clinical trials in the US to support its upcoming clinical trials in the US. The test also found that the Caucasian population had better safety tolerance than the Chinese population.

Zhitongcaijing · 2d ago
Zhitong Finance App News, Luye Pharmaceutical (02186.HK) announced that LY03015, a new molecular entity independently developed by the Group, has successfully completed bridging clinical trials in the US to support its upcoming clinical trials in the US. The test also found that the Caucasian population had better safety tolerance than the Chinese population.